Accuray Incorporated (ARAY)

Currency in USD
0.856
-0.032(-3.60%)
Closed·
0.900+0.044(+5.14%)
·
Unusual Post-Market activity
Unusual trading volume
Trading near 52-week Low
ARAY is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.8100.888
52 wk Range
0.8102.950
Key Statistics
Prev. Close
0.856
Open
0.885
Day's Range
0.81-0.888
52 wk Range
0.81-2.95
Volume
2.43M
Average Volume (3m)
1.12M
1-Year Change
-54.22%
Book Value / Share
0.55
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ARAY Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
3.875
Upside
+352.69%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory

Accuray Incorporated News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Accuray Company Profile

Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. It also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, the company offers post-contract customer support, installation, training, and other professional services. It primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.

Accuray Incorporated Earnings Call Summary for Q1/2026

  • Accuray reported Q1 FY2026 EPS of -$0.18, missing the -$0.05 forecast by 260%, while revenue reached $93.94M, slightly exceeding expectations despite a 7% YoY decline.
  • Despite the earnings miss, shares rose 5.43% in after-hours trading to $1.42, as investors responded positively to revenue performance and strategic initiatives.
  • The company experienced significant margin pressure with gross margin falling 5.6 percentage points YoY to 28.3%, while operating loss widened to $11.3M from $2.1M last year.
  • Management forecasts FY2026 revenue between $471M-$485M and adjusted EBITDA of $31M-$35M, with plans to unveil a transformation strategy in early 2026.
  • CEO Steve Leneve announced a strategic restructuring plan focused on operational efficiency and margin expansion, targeting high single-digit adjusted EBITDA margins within 12 months.
Last Updated: 05/11/2025, 22:32
Read Full Transcript

Compare ARAY to Peers and Sector

Metrics to compare
ARAY
Peers
Sector
Relationship
P/E Ratio
−5.0x16.3x−0.6x
PEG Ratio
0.640.010.00
Price/Book
1.6x4.0x2.6x
Price / LTM Sales
0.2x3.3x3.2x
Upside (Analyst Target)
352.7%51.1%41.8%
Fair Value Upside
Unlock20.8%5.1%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 3.875
(+352.69% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
BTIG
Buy4.00+367.29%5.00Maintain06/11/2025
BTIG
Buy5.00+484.11%4.00Maintain14/08/2025
BTIG
Buy4.00+367.29%5.00Maintain06/06/2025

Earnings

Latest Release
Nov 05, 2025
EPS / Forecast
-0.18 / -0.05
Revenue / Forecast
93.94M / 91.35M
EPS Revisions
Last 90 days

People Also Watch

97.99
HOV
-0.42%
61.47
BXC
+0.99%
56.67
TCI
-3.64%
3.58
ANVS
-8.91%

FAQ

What Is the Accuray (ARAY) Share Price Today?

The live Accuray share price today is 0.856

What Stock Exchange Does Accuray (ARAY) Trade On?

Accuray is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Accuray?

The stock symbol (also called a 'ticker') for Accuray is "ARAY."

What Is the Current Accuray Market Cap?

As of today, Accuray market capitalisation is 97.02M.

What Is Accuray's (ARAY) Earnings Per Share (TTM)?

The Accuray EPS is currently -0.18 (Trailing Twelve Months).

When Is the Next Accuray Earnings Date?

Accuray's next earnings report will be released on 04 Feb 2026.

Is ARAY a Buy or Sell From a Technical Analyst Perspective?

Based on today's Accuray moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Accuray Stock Split?

Accuray has split 0 times. (See the ARAY stock split history page for full effective split date and price information.)

How Many Employees Does Accuray Have?

Accuray has 990 employees.

What is the current trading status of Accuray (ARAY)?

As of 24 Dec 2025, Accuray (ARAY) is trading at a price of 0.856, with a previous close of 0.856. The stock has fluctuated within a day range of 0.810 to 0.888, while its 52-week range spans from 0.810 to 2.950.

What Is Accuray (ARAY) Price Target According to Analysts?

The average 12-month price target for Accuray is USD3.875, with a high estimate of USD4 and a low estimate of USD3.75. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +352.69% Upside potential.

What Is the ARAY After Hours Price?

ARAY's last after hours stock price is 0.900, the stock has decreased by 0.044, or 5.140%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.